Aligned Education Improves Patient Outcomes Across CME Programs

As the treatment landscape for neuromuscular physiology and diseases evolves, PlatformQ Health has been at the forefront of patient and provider education, delivering programming that drives improved patient experiences and shared decision making.

Numerous posters of educational outcomes have been published at major conferences over the past three years across neuromuscular conditions, including duchenne muscular dystrophy (DMD), myasthenia gravis (gMG), and spinal muscular atrophy (SMA). These posters highlight the advantages of aligned patient/provider education for closing knowledge gaps and aligning expectations between patients and providers.

Educational Outcomes In MG

In partnership with NORD, the Myasthenia Gravis Foundation of American, and Muscular Dystrophy Association, PlatformQ Health produced aligned patient/provider educational programs featuring key opinion leaders as well as a patient. Published poster highlights include:

American Association of Neuromuscular & Electrodiagnostic Medicine Poster 2023

Program title: Individualizing Therapy for Generalized Myasthenia Gravis: Can Continuing Medical Education Help Guide Treating Clinicians?

Result highlights:

  • 2,241 learners
  • 904 micro-learners
  • 56% Neurologists
American Association of Neuromuscular & Electrodiagnostic Medicine Poster 2022

Program title: Evolving Treatment Approaches for Generalized Myasthenia Gravis to Reduce Disease Burden and Improve Daily Living

Result highlights:

  • 752 total learners
  • 414 self-identified as treaters
  • 255 certificates awarded
  • 35:53 average time in session
  • More than 50% increase in knowledge/competence post-session
World Muscle Society poster

Program title: Applying Enhanced Understanding of the Mechanisms of Disease in gMG: Improved Diagnostics and Targeted Treatment Options

Result highlights:

  • 906 learners
  • 63% physicians and advanced practitioners
  • 45%+ increase in learner knowledge/competence post-session

Educational Outcomes In SMA

The emergence of disease-modifying therapies has changed the treatment of patients with SMA. PlatformQ Health, NORD, and CureSMA produced three aligned provider and patient/caregiver education programs highlighting emerging disease-modifying therapies as well as the need for multidisciplinary care. Published poster highlights include:

AAN poster

Program title: Spinal Muscular Atrophy: A New Era for Both Patients and Clinicians

Result highlights:

  • 56% of HCP learners reported the activity positively impacted patient experience outcomes.
  • 64% of caregivers reported feeling more informed and confident in their health-related decisions.
National Institutes of Health poster

Program title: Improving Outcomes in Spinal Muscular Atrophy: Best Practices for Clinicians and Families

Result highlights:

  • 9,510 total engagement
  • 934 HCP learners
  • Post-education, 100% of learners supported models of shared decision making, compared to 88% pre-education.
AAN poster

Program title: Collaborative Care in SMA: Evolving Roles for Neurologists, Ob‐Gyns, PCPs, and Counselors

Result highlights:

  • 23,688 total engagements
  • 48% HCPs
  • 91% of learners reported the activity positively impacted clinical practice as well as patient experiences/outcomes.

Educational Outcomes In DMD

Emerging guidelines and therapeutic advances have brought about competency gaps in understanding mutation-specific treatments and more in the treatment of patients with DMD. The National Organization for Rare Disorders (NORD), CureSMA, and PlatformQ Health produced several programs focused on early diagnosis and intervention. Published poster highlights include:

American Academy of Neurology (AAN) poster

Program title: Duchenne Muscular Dystrophy – An Expanding Lifespan

Result highlights:

  • 82% of learners reported the activity positively impacted patient experiences/outcomes
  • 84% of learners reported the activity positively impacted clinical practice
World Muscle Society poster

Program title: The Era of Disease-Modifying Therapy for Duchenne Muscular Dystrophy: Outlining Care Pathways for the Evolving Needs of the Patient

Result highlights:

  • 42% and 22% increase in competence of recognizing DMD signs and symptoms
  • 29% and 9% increase in knowledge about dystrophin mutations common to DMD

_____________________________________________________________________________________________

Have questions about a poster or want to learn more about how PlatformQ Health is delivering impactful education to HCPs and patients? Email us at digital@platformq.com. 

Post navigation